Literature DB >> 27356905

Major Histocompatibility Complex Class II HLA-DRα Is Downregulated by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Lytic Transactivator RTA and MARCH8.

Zhiguo Sun1, Hem Chandra Jha1, Yong-Gang Pei1, Erle S Robertson2.   

Abstract

UNLABELLED: Kaposi's sarcoma-associated herpesvirus (KSHV) maintains two modes of life cycle, the latent and lytic phases. To evade the attack of the cell host's immune system, KSHV switches from the lytic to the latent phase, a phase in which only a few of viral proteins are expressed. The mechanism by which KSHV evades the attack of the immune system and establishes latency has not been fully understood. Major histocompatibility complex class II (MHC-II) molecules are key components of the immune system defense mechanism against viral infections. Here we report that HLA-DRα, a member of the MHC-II molecules, was downregulated by the replication and transcription activator (RTA) protein encoded by KSHV ORF50, an important regulator of the viral life cycle. RTA not only downregulated HLA-DRα at the protein level through direct binding and degradation through the proteasome pathway but also indirectly downregulated the protein level of HLA-DRα by enhancing the expression of MARCH8, a member of the membrane-associated RING-CH (MARCH) proteins. Our findings indicate that KSHV RTA facilitates evasion of the virus from the immune system through manipulation of HLA-DRα. IMPORTANCE: Kaposi's sarcoma-associated herpesvirus (KSHV) has a causal role in a number of human cancers, and its persistence in infected cells is controlled by the host's immune system. The mechanism by which KSHV evades an attack by the immune system has not been well understood. This work represents studies which identify a novel mechanism by which the virus can facilitate evasion of an immune system. We now show that RTA, the replication and transcription activator encoded by KSHV (ORF50), can function as an E3 ligase to degrade HLA-DRα. It can directly bind and induce degradation of HLA-DRα through the ubiquitin-proteasome degradation pathway. In addition to the direct regulation of HLA-DRα, RTA can also indirectly downregulate the level of HLA-DRα protein by upregulating transcription of MARCH8. Increased MARCH8 results in the downregulation of HLA-DRα. Furthermore, we also demonstrate that expression of HLA-DRα was impaired in KSHV de novo infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27356905      PMCID: PMC5008100          DOI: 10.1128/JVI.01079-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Identification and analysis of the K5 gene of Kaposi's sarcoma-associated herpesvirus.

Authors:  M Haque; J Chen; K Ueda; Y Mori; K Nakano; Y Hirata; S Kanamori; Y Uchiyama; R Inagi; T Okuno; K Yamanishi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 3.  The ubiquitin system.

Authors:  A Hershko; A Ciechanover
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development.

Authors:  Maria Caterina Sirianni; Fabio Libi; Massimo Campagna; Davide Rossi; Daniela Capello; Gaia Sciaranghella; Antonio Carbone; Cecilia Simonelli; Paolo Monini; Gianluca Gaidano; Barbara Ensoli
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

5.  Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency.

Authors:  Ke Lan; Daniel A Kuppers; Subhash C Verma; Nikhil Sharma; Masanao Murakami; Erle S Robertson
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Cutting edge: the role of IFN-α receptor and MyD88 signaling in induction of IL-15 expression in vivo.

Authors:  Sara L Colpitts; Thomas A Stoklasek; Courtney R Plumlee; Joshua J Obar; Caiying Guo; Leo Lefrançois
Journal:  J Immunol       Date:  2012-02-10       Impact factor: 5.422

7.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

8.  The RBP-Jκ binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation.

Authors:  Jie Lu; Subhash C Verma; Qiliang Cai; Abhik Saha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2012-01-12       Impact factor: 6.823

9.  IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation.

Authors:  Qiliang Cai; Shuvomoy Banerjee; Amanda Cervini; Jie Lu; Andrew D Hislop; Richard Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  The HLA-DRalpha chain is modified by polyubiquitination.

Authors:  Nicolas Lapaque; Martin Jahnke; John Trowsdale; Adrian P Kelly
Journal:  J Biol Chem       Date:  2008-12-31       Impact factor: 5.157

View more
  10 in total

1.  Molecular Biology of KSHV in Relation to HIV/AIDS-Associated Oncogenesis.

Authors:  Meilan He; Fan Cheng; Suzane Ramos da Silva; Brandon Tan; Océane Sorel; Marion Gruffaz; Tingting Li; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2019

2.  MARCH8 is associated with poor prognosis in non-small cell lung cancers patients.

Authors:  Jiye Fan; Liying Tian; Manli Li; Shu-Hong Huang; Jing Zhang; Baohua Zhao
Journal:  Oncotarget       Date:  2017-11-21

3.  ZIC2 Is Essential for Maintenance of Latency and Is a Target of an Immediate Early Protein during Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivation.

Authors:  Yuanzhi Lyu; Kazushi Nakano; Ryan R Davis; Clifford G Tepper; Mel Campbell; Yoshihiro Izumiya
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

4.  Identification of potential crucial genes and key pathways in osteosarcoma.

Authors:  Junwei Liu; Siyu Wu; Xiaoyu Xie; Ziming Wang; Qianqian Lei
Journal:  Hereditas       Date:  2020-07-14       Impact factor: 3.271

5.  Expression profile analysis identifies key genes as prognostic markers for metastasis of osteosarcoma.

Authors:  Xiaoqing Guan; Zhiyuan Guan; Chunli Song
Journal:  Cancer Cell Int       Date:  2020-03-30       Impact factor: 5.722

Review 6.  When MARCH family proteins meet viral infections.

Authors:  Chunfu Zheng; Yan-Dong Tang
Journal:  Virol J       Date:  2021-03-02       Impact factor: 4.099

7.  Molecular Mechanisms of Kaposi Sarcoma Development.

Authors:  Andy Karabajakian; Isabelle Ray-Coquard; Jean-Yves Blay
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

8.  KSHV RTA antagonizes SMC5/6 complex-induced viral chromatin compaction by hijacking the ubiquitin-proteasome system.

Authors:  Chunyan Han; Dun Zhang; Chenwu Gui; Liang Huang; Sijia Chang; Lianghui Dong; Lei Bai; Shuwen Wu; Ke Lan
Journal:  PLoS Pathog       Date:  2022-08-01       Impact factor: 7.464

9.  Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide.

Authors:  David A Davis; Suraj Mishra; Holda A Anagho; Ashley I Aisabor; Prabha Shrestha; Victoria Wang; Yuki Takamatsu; Kenji Maeda; Hiroaki Mitsuya; Jerome B Zeldis; Robert Yarchoan
Journal:  Oncotarget       Date:  2017-05-17

Review 10.  KSHV: Immune Modulation and Immunotherapy.

Authors:  Grant Broussard; Blossom Damania
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.